200 related articles for article (PubMed ID: 25741704)
1. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.
Blake SJ; Ching AL; Kenna TJ; Galea R; Large J; Yagita H; Steptoe RJ
PLoS One; 2015; 10(3):e0119483. PubMed ID: 25741704
[TBL] [Abstract][Full Text] [Related]
2. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice.
Ge Y; Xi H; Ju S; Zhang X
Cancer Lett; 2013 Aug; 336(2):253-9. PubMed ID: 23523609
[TBL] [Abstract][Full Text] [Related]
3. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
[TBL] [Abstract][Full Text] [Related]
4. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.
Pauken KE; Nelson CE; Martinov T; Spanier JA; Heffernan JR; Sahli NL; Quarnstrom CF; Osum KC; Schenkel JM; Jenkins MK; Blazar BR; Vezys V; Fife BT
J Immunol; 2015 Apr; 194(8):3551-3555. PubMed ID: 25769925
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes.
Liu Q; Lv Y; Zhao M; Jin Y; Lu J
Int J Clin Exp Pathol; 2015; 8(2):1374-83. PubMed ID: 25973021
[TBL] [Abstract][Full Text] [Related]
6. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
7. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
[TBL] [Abstract][Full Text] [Related]
8. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance.
Diehl L; Schurich A; Grochtmann R; Hegenbarth S; Chen L; Knolle PA
Hepatology; 2008 Jan; 47(1):296-305. PubMed ID: 17975811
[TBL] [Abstract][Full Text] [Related]
9. Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.
Kaiser AD; Schuster K; Gadiot J; Borkner L; Daebritz H; Schmitt C; Andreesen R; Blank C
Eur J Immunol; 2012 Mar; 42(3):662-71. PubMed ID: 22144176
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner.
Charlton JJ; Chatzidakis I; Tsoukatou D; Boumpas DT; Garinis GA; Mamalaki C
J Immunol; 2013 Jun; 190(12):6104-14. PubMed ID: 23686498
[TBL] [Abstract][Full Text] [Related]
12. Overcoming T cell exhaustion in infection and cancer.
Pauken KE; Wherry EJ
Trends Immunol; 2015 Apr; 36(4):265-76. PubMed ID: 25797516
[TBL] [Abstract][Full Text] [Related]
13. Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions.
Moret FM; van der Wurff-Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA
Arthritis Res Ther; 2014 Nov; 16(6):497. PubMed ID: 25433812
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.
Li W; Wang X; Chen R; Zhu H; Chen G; Sun X
J Surg Res; 2012 Aug; 176(2):e79-87. PubMed ID: 22381170
[TBL] [Abstract][Full Text] [Related]
15. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
Wang Q; Wu X
Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells transfected with PD-L1 recombinant adenovirus induces T cell suppression and long-term acceptance of allograft transplantation.
Peng W; Ran B; Ma Y; Huang X; Chang Q; Wang X
Cell Immunol; 2011; 271(1):73-7. PubMed ID: 21855860
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
[TBL] [Abstract][Full Text] [Related]
18. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
[TBL] [Abstract][Full Text] [Related]
19. IgA plasma cells express the negative regulatory co-stimulatory molecule programmed cell death 1 ligand and have a potential tolerogenic role in the intestine.
Doi T; Kanai T; Mikami Y; Sujino T; Jun L; Ono Y; Hayashi A; Hibi T
Biochem Biophys Res Commun; 2012 Sep; 425(4):918-23. PubMed ID: 22906740
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and its ligands in T-cell immunity.
Keir ME; Francisco LM; Sharpe AH
Curr Opin Immunol; 2007 Jun; 19(3):309-14. PubMed ID: 17433872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
